- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05300633
Community Reinforcement Approach and Family Training for Substance Use in Early Psychosis Intervention (CRAFT-EPI)
Adapting Community Reinforcement Approach and Family Training to Target Substance Use in Early Psychosis Intervention: A Pilot Study of Group Therapy
Study Overview
Status
Conditions
Detailed Description
Substance use has a major impact on the prevalence and course of early psychosis in young people. Substance use disorders occur in over 40% of people with schizophrenia spectrum disorders. There is increasing evidence to support the fact that cannabis can trigger and worsen psychosis. Young people with psychosis who have comorbid substance use disorders are known to experience worse outcomes, with a three-fold risk of psychosis relapse compared to those without substance use disorders. Current Canadian guidelines recommend integration of substance use treatments in early psychosis intervention programs and specifically suggest integrating addiction-based psychosocial interventions, and involving families in care, but there is limited evidence to support any one specific psychosocial intervention in this population. Studies show that around half of young people with psychosis who use substances significantly reduce their use with the general education and advice provided in early psychosis intervention programs, but it is unclear how programs should intervene to support the other half of clients who continue to struggle.
Community Reinforcement Approach and Family Training (CRAFT) grew out of the understanding that individuals with substance use disorders often struggle with treatment-seeking motivation, whereas their family members are typically highly motivated to get help for them. Having a young person in the family with a substance use disorder can be a very distressing experience, leading to marital and family conflict, physical and verbal abuse, financial problems, and mental health problems for their family members. CRAFT helps family members change the family environment in such a way that a non-substance using lifestyle is more rewarding than one focused on the use of substances. CRAFT aims to improve family members' understanding of addiction, learn about their own behaviors that may unintentionally be promoting substance use, and to modify their own behavior to foster a supportive environment. The ultimate goals are to increase the motivation of the person with the substance use disorder to seek help, and to decrease their substance use. CRAFT teaches family members, who often lack support, how to better take care of themselves and their mental health, and increase their happiness independent of whether their loved one enters substance use treatment.
The efficacy of CRAFT has been demonstrated in multiple research trials, with high rates of individuals with substance use disorders entering treatment. Importantly, the treatment engagement outcomes are effective regardless of the age of the family member or their relationship to the identified patient, and the identified patient's substance of choice. While the therapy is typically provided to families one at a time, it has been adapted to be delivered in groups with equivalent efficacy and the added advantage of reaching more families and built-in peer support.
Families who have completed a basic psychoeducation group at the Centre for Addiction and Mental Health (CAMH) Slaight Centre for Early Intervention (SCEI) and are concerned about their identified patient's substance use will be offered participation in a study of group CRAFT. The intervention has been adapted for early psychosis by Dr. Julie McCarthy at McLean Hospital. It will consist of an individual orientation session, 6 weekly group sessions, and a booster session. Families' satisfaction with this model, changes in their level of stress, quality of life, and other outcomes, and the patients' readiness to change, substance use, and engagement in substance use treatment will be evaluated. Families and patients will complete assessments at baseline, post-intervention, and 12-week follow-up. Families will additionally be invited to participate in a focus group that explores their experience of the intervention.
The goal of this pilot feasibility and proof of concept study is to evaluate whether CRAFT as adapted for group delivery in an EPI program has a clinically significant impact on the family and identified patient, and whether a larger, definitive trial is feasible. This intervention has the potential to fill a major gap in early psychosis intervention, improving outcomes for both youth and families.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M6J1H1
- Centre for Addiction and Mental Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Concerned significant other (CSO)
- Adult (at least 18 years) family member of an identified patient (IP) enrolled in SCEI treatment. The IP should be aged 16-29 years with clinician diagnosis of early psychosis (schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar I disorder, major depressive disorder with psychotic features, substance-induced psychotic disorder, or unspecified schizophrenia spectrum and other psychotic disorder). The IP does NOT need to be enrolled in the study in order for the CSO to participate. Up to 2 CSOs associated with the same IP may participate.
- Has completed the program's introductory psychoeducation group
- Concerned about substance use in the IP enrolled in the early psychosis intervention program
Identified patient
- Enrolled in the early psychosis intervention program, aged 16-29 years with clinician diagnosis of early psychosis (schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar I disorder, major depressive disorder with psychotic features, substance-induced psychotic disorder, or unspecified schizophrenia spectrum and other psychotic disorder)
- Not currently receiving specialized substance use treatment (i.e. by a clinician other than their NAVIGATE clinicians)
Exclusion Criteria:
Concerned significant other
- Inability to provide informed consent
- Inability to communicate in basic oral and written English.
- There are already 2 CSOs associated with a given IP that are participating in the CRAFT-EPI study.
- Lack of a device for videoconferencing and a secure Wi-Fi connection
- Unwilling to turn camera on for weekly group sessions (except in the case of a poor Wi-Fi connection, or other similar circumstances)
Identified patient
- Does not have a CSO that is enrolled in the CRAFT-EPI study
- Inability to provide informed consent
- Inability to communicate in basic oral and written English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention arm
Family member/concerned significant other
|
Behavioral therapy adapted for families of young people experiencing early psychosis delivered via telemedicine to groups following an individual orientation.
Group session topics include self-care, communication, functional analysis, positive reinforcement, treatment engagement, natural consequences, and problem solving.
A happiness scale will be completed at each session.
Will be provided in the context of an early psychosis intervention program that provides coordinated specialty care to 16- to 29-year-olds experiencing any diagnosis that can manifest as early psychosis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of treatment entry for substance use
Time Frame: 18 weeks
|
Treatment entry for substance use by the identified patient as reported by their family member (concerned significant other)
|
18 weeks
|
Rates of recruitment
Time Frame: Baseline
|
Number of family member and identified patient participants who consent to participation
|
Baseline
|
Rates of retention
Time Frame: 18 weeks
|
Number of family member participants who complete 6 intervention sessions and booster session
|
18 weeks
|
Rates of assessment completion
Time Frame: 18 weeks
|
Proportion of assessments completed by consented family members and identified patients, averaged over 3 timepoints
|
18 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Health Questionnaire (PHQ-9) total score
Time Frame: Baseline, 6 weeks, 18 weeks
|
Symptoms of depression
|
Baseline, 6 weeks, 18 weeks
|
Happiness Scale total score
Time Frame: Baseline, 6 weeks, 18 weeks
|
Experience of happiness
|
Baseline, 6 weeks, 18 weeks
|
Perceived Stress Scale-14 item total score
Time Frame: Baseline, 6 weeks, 18 weeks
|
Experience of stress
|
Baseline, 6 weeks, 18 weeks
|
Ontario Perception of Care Tool-Mental Health and Addictions section scores
Time Frame: 6 weeks, 18 weeks
|
Perceptions of care, satisfaction with the model
|
6 weeks, 18 weeks
|
Contemplation Ladder total score
Time Frame: Baseline, 6 weeks, 18 weeks
|
Readiness to change substance use
|
Baseline, 6 weeks, 18 weeks
|
National Institute on Drug Abuse (NIDA)-Modified Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) V2.0 total score
Time Frame: Baseline, 6 weeks, 18 weeks
|
Substance use
|
Baseline, 6 weeks, 18 weeks
|
Generalized Anxiety Disorder-7 (GAD-7) total score
Time Frame: Baseline, 6 weeks, 18 weeks
|
Symptoms of anxiety
|
Baseline, 6 weeks, 18 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Nicole Kozloff, MD, SM, Centre for Addiction and Mental Health
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 127-2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia Spectrum and Other Psychotic Disorders
-
VA Office of Research and DevelopmentCompletedSchizophrenia Spectrum & Other Psychotic DisordersUnited States
-
New York State Psychiatric InstituteTemple University; The Zucker Hillside Hospital; Feinstein Institutes for Medical...Not yet recruitingSchizophrenia | Schizoaffective Disorder | Delusional Disorder | Schizophreniform Disorders | Other Specified Schizophrenia Spectrum and Other Psychotic Disorder
-
University of North Carolina, Chapel HillNorth Carolina Department of Health and Human ServicesCompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorders | Unspecified Schizophrenia Spectrum and Other Psychotic DisorderUnited States
-
Laval UniversityCompletedSchizophrenia and Schizophrenia Spectrum PsychosisCanada
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorders | Unspecified Schizophrenia Spectrum and Other Psychotic Disorder | Brief Psychotic DisorderUnited States
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorder | Unspecified Schizophrenia Spectrum and Other Psychotic Disorder | Brief Psychotic DisorderUnited States
-
Columbia UniversityNational Institute of Mental Health (NIMH)RecruitingSchizophrenia | Schizo Affective Disorder | Delusional Disorder | Schizophreniform Disorders | Other Specified Schizophrenia Spectrum and Other Psychotic DisorderUnited States
-
Stanford UniversityCompletedPsychotic Disorders | Schizophrenia Spectrum DisordersUnited States
-
University of California, Los AngelesCompletedSchizophrenia Spectrum
-
University of California, San DiegoNational Alliance for Research on Schizophrenia and DepressionCompletedSchizophrenia | Schizoaffective Disorder | Other Primary Psychotic DisordersUnited States
Clinical Trials on Group-Based Community Reinforcement Approach and Family Training-Early Psychosis Intervention (CRAFT-EPI)
-
Mclean HospitalNational Institute on Drug Abuse (NIDA)RecruitingSchizophrenia | Schizoaffective Disorder | Bipolar Disorder | Cannabis | Substance Use | Substance Use Disorders | Psychosis | Mental Disorder | Family | Marijuana | AlcoholUnited States
-
Stanford UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); University of Southern... and other collaboratorsRecruitingAlcohol Drinking | Alcohol Use Disorder | Alcohol Abuse | Military Family | Relations, InterpersonalUnited States
-
Treatment Research InstituteNational Institute on Drug Abuse (NIDA); Robert J. Meyers PhD & AssociatesCompletedSubstance-Related Disorders | Substance Abuse | Drug AddictionUnited States
-
Colchester East Hants Health AuthorityUniversity of Calgary; Dalhousie University; Pictou County Health AuthorityWithdrawnPathological GamblingCanada
-
We The Village, Inc.Public Health Management CorporationCompletedSubstance-Related Disorders | Family Health | Community Reinforcement And Family TrainingUnited States
-
Washington University School of MedicineNational Institute of Mental Health (NIMH); University of California, San FranciscoRecruiting